Back

Replimune shares plunge 64.29% after FDA rejects RP1 application

Verifying
  • FDA rejected Replimune’s RP1 application combined with nivolumab on April 10, 2026.
  • Replimune shares fell 64.29% to $1.70 on April 13, 2026.
  • Investors bought during October 20-April 10 can file lead plaintiff motions by October 5.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.